Satis Group S.A. (WSE:STS)

Orchard Therapeutics Cash Flow Statement

Financials in millions PLN. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Net Income	-264.25	-264.19	-9.11	-0.73	270.73	0.7
Other Operating Activities	-	-	-	-0.02	-	-
Change in Accounts Receivable	-0.12	-0.14	-1.18	0.26	0.95	-0.73
Change in Other Net Operating Assets	264.39	263.82	8.89	0.05	-270.87	0.17
Operating Cash Flow	0.01	-0.5	-1.4	-0.45	0.82	0.14
Operating Cash Flow Growth	10.00%	-	-	-	503.68%	-
Investment in Securities	-0.63	-	-	-	-	-
Other Investing Activities	0.48	0.48	0	-	0.15	-
Investing Cash Flow	-0.15	0.48	0	-	-0.45	-0.12
Short-Term Debt Issued	-	0.02	-	0.32	4.89	0.08
Total Debt Issued	0.14	0.02	-	0.32	4.89	0.08
Short-Term Debt Repaid	-	-	-0.01	-0.27	-5.02	-
Total Debt Repaid	-	-	-0.01	-0.27	-5.02	-
Net Debt Issued (Repaid)	0.14	0.02	-0.01	0.06	-0.13	0.08
Issuance of Common Stock	-	-	1.4	-	-	-
Financing Cash Flow	0.14	0.02	1.39	0.06	-0.13	0.08
Net Cash Flow	-0	-0	-0.01	-0.39	0.24	0.1
Free Cash Flow	0.01	-0.5	-1.4	-0.45	0.82	0.14
Free Cash Flow Growth	10.00%	-	-	-	503.68%	-
Free Cash Flow Margin	-	-	-	-17.84%	37.89%	4.83%
Free Cash Flow Per Share	0.00	-0.04	-0.10	-0.04	0.07	0.01
Levered Free Cash Flow	98.7	98.73	1.84	-0.34	-270.83	-0.37
Unlevered Free Cash Flow	98.82	98.85	3	-0.25	-270.73	-0.29

Source: S&P Global Market Intelligence. Standard template. Financial Sources.